Neuropeptide levels in Alzheimer’s disease and dementia with frontotemporal degeneration

  • L. Minthon
  • L. Edvinsson
  • R. Ekman
  • L. Gustafson
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 30)


The CSF levels of somatostatin-LI (SLI), neuropeptide Y (NPY-LI) and Delta Sleep Inducing Peptide (DSIP-LI) have been measured in patients with dementia of Alzheimer type (DAT) and dementia with frontotemporal degeneration of non-Alzheimer type (FTD). The distribution pattern of cortical degeneration differs between these two types of dementia. DAT shows degeneration of mainly temporo-parietal and temporo-limbic structures, whereas FTD discloses its main degeneration in the frontotemporal regions (Brun, 1987). The somatostatin-LI was significantly reduced both in DAT and FTD. NPY-LI showed a significant reduction in DAT but not in FTD. A tendency to a reduction with duration of the disease was observed in DAT whereas the contrary was noted in FTD. The DSIP-LI levels were reduced in DAT and slightly increased in FTD. The study provides an evidence of neurochemical differences between the two primary degenerative dementias.


High Performance Liquid Chroma High Performance Liquid Chroma Delta Sleep Induce Peptide Diagnostic Score Ischemic Score 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Beal MF, Mazurek MF, McKee MA (1987) The regional distribution of somatostatin and neuropeptide Y in control and Alzheimer’s disease striatum. Neurosci Lett 79: 201–206PubMedCrossRefGoogle Scholar
  2. Brun A, Gustafson L (1976) Distribution of cerebral degeneration in Alzheimer’s disease. A clinico-pathological study. Arch Psychiatr Nervenkr 223:15–33PubMedCrossRefGoogle Scholar
  3. Brun A, Englund E (1981) Regional pattern of degeneration in Alzheimer’s disease: neuronal loss and histopathological grading. Histopathology 5:549–564PubMedCrossRefGoogle Scholar
  4. Brun A (1987) Frontal lobe degeneration of non-Alzheimer type. I. Neuropathology. Arch Gerontol Geriatr 6:193–208CrossRefGoogle Scholar
  5. Brun A (1987) Frontal lobe degeneration of non-Alzheimer type. I. Clinical picture and differential diagnosis. Arch Gerontol Geriatr 6:193–208PubMedCrossRefGoogle Scholar
  6. Brun A, Gustafson L (1988) Zerebrovaskuläre Erkrankungen. In: Kisker KP, et al (Hrsg) Psychiatrie der Gegenwart. Organische Psychosen. Springer, Berlin Heidelberg New York Tokyo, S 253–295Google Scholar
  7. Davies P, Katzman R, Terry RD (1980) Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer’s disease and Alzheimer senile dementia. Nature 288:279–280PubMedCrossRefGoogle Scholar
  8. Ekman R, Larsson I, Malmquist M, Thorell J (1983) Radioimmunoassay of deltasleep-inducing peptide using an iodinated p-hydroxyphenylpropionic acid derivative as tracer. Regul Pept 6: 371–378PubMedCrossRefGoogle Scholar
  9. Ekman R, Wahlestedt C, Böttcher G, Sundler F, Hakånson R, Panula P (1986) Peptide YY-like immunoreactivity in the central nervous system of the rat. Regul Pept 16:157–168PubMedCrossRefGoogle Scholar
  10. Gustafson L, Risberg J, Johanson M, et al (1984) Evaluation of organic dementia by regional cerebral blood flow measurements and clinical and psychometric methods. In: Fieschi C, et al (eds) Effects of aging on regulation of cerebral blood flow and metabolism. Monogr Neural Sci 11:111–117Google Scholar
  11. Gustafson L (1987) Frontal lobe degeneration of non-Alzheimer type. I. Clinical picture and differential diagnosis. Arch Gerontol Geriatr 6:209–223PubMedCrossRefGoogle Scholar
  12. Gustafson L, Brun A (1989) The Scandinavian view. In: Hovaguimian T, et al (eds) Classification and diagnosis of Alzheimer disease: an international perspective. Hogrefe and Huber, Toronto Lewiston NY Bern Stuttgart Göttingen, pp 17–23Google Scholar
  13. Gustafson L, Nilsson L (1982) Differential diagnosis in presenile dementia on clinical grounds. Acta Psychiatr Scand 65:194–209PubMedCrossRefGoogle Scholar
  14. Hachinski VC, Iliff LD, Zilka E, et al (1975) Cerebral blood flow in dementia. Arch Neurol 32: 632–637PubMedCrossRefGoogle Scholar
  15. Kafi S, Monnier M, Gaillard J-M (1979) The delta sleep inducing peptide (DSIP) increase duration of sleep in rats. Neurosci Lett 13:169–172PubMedCrossRefGoogle Scholar
  16. Marcus V, Graf A, Kastin A (1986) Delta-sleep-inducing peptide (DSIP): an update. Peptides 7:1165–1187CrossRefGoogle Scholar
  17. Monnier M, Koller T, Graber S (1963) Humoral influence of induced sleep and arousal upon electrical brain activity of animals with cross circulation. Exp Neurol 8:264–277CrossRefGoogle Scholar
  18. Monnier M, Dudler L, Gächter R, Schoenenberger G (1977) Delta sleep inducing peptide (DSIP). EEG and motor activity in rabbits following intravenous administration. Neurosci Lett 5:9–13CrossRefGoogle Scholar
  19. Nakamura S, Vincent SR (1986) Somatostatin- and neuropeptide Y-immunoreactive neurons in the neocortex in senile dementia of Alzheimer’s type. Brain Res 370:11–20PubMedCrossRefGoogle Scholar
  20. Risberg J (1980) Regional cerebral blood flow measurements by 133 Xe inhalation: methodology and applications in neuropsychiatry and psychiatry. Brain Lang 9:9–34PubMedCrossRefGoogle Scholar
  21. Risberg J, Gustafson L (1982) 133 Xe cerebral blood blow in dementia and in neuropsychiatry research. In: Magistretti PL (ed) Functional radionuclide imaging of the brain. Raven Press, New York, pp 151–158Google Scholar
  22. Risberg J (1987) Frontal lobe degeneration of non-Alzheimer type. III. Regional cerebral blood flow. Arch Gerontol Geriatr 6:225–233PubMedCrossRefGoogle Scholar
  23. Rossor MN, Ellison PC, Mountjoy CQ, et al (1980) Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer type. Neurosci Lett 20:373–377PubMedCrossRefGoogle Scholar
  24. Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger G (1981) Acute and delayed effect of DSIP (delta sleep inducing peptide) on human sleep behaviour. Int J Clin Pharmacol Ther Toxicol 19:341–345PubMedGoogle Scholar
  25. Wallengren J, Ekman R, Sundler F (1987) Occurrence and distribution of neuropeptides in the human skin. Acta Derm Venereol 67:551–558Google Scholar
  26. Widerlöv E, Lindström H, Wahlestedt C, Ekman R (1988) Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J Psychiatr Res 22(1):69–79PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • L. Minthon
    • 1
    • 4
  • L. Edvinsson
    • 2
  • R. Ekman
    • 3
  • L. Gustafson
    • 1
  1. 1.Departments of PsychogeriatricsUniversity of LundLundSweden
  2. 2.Internal MedicineUniversity of LundLundSweden
  3. 3.Psychiatry and NeurochemistryUniversity of LundLundSweden
  4. 4.Department of PsychogeriatricsUniversity of LundLundSweden

Personalised recommendations